What Is Genomics?
Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.
Your trusted source for investing success
Your trusted source for investing success
Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
Krystal Biotech announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.
The Investing News Network (INN) takes a closer look at the top biotech companies listed on the NASDAQ so far this year, with a market cap between 50 and 500 million.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Voyager Therapeutics announced positive results from their ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.
Oncology investing can certainly be intimidating. Here, the Investing News Network looks at companies in the space and other ways to invest.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Abeona Therapeutics announced the US Food and Drug Administration granted a Breakthrough Therapy designation status to the company’s EB-101 gene therapy program.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
The US Food and Drug Administration granted Seattle Genetics’ ADCETRIS treatment a Biologics License Application and gave the gene therapy a priority review scheduled later this year.
Abeona Therapeutics announced an expansion to its gene therapy clinical trials for patients with MPS IIIA in the US, Europe, and Australia.
Abeona Therapeutics shared their financial results for the second quarter of 2017 and provided a business update to shareholders.
Fortress Biotech announced the creation of a new subsidiary called Aevitas Therapeutics.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership with the genetics company.
Doug Casey, Brent Cook, Adrian Day, Matt Badiali, Keith Fitz-Gerald, Chris Gaffney and Byron King discuss their investment ideas and top stock picks for 2017.
Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.
Click here to get your free report!Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.
